Table 2

Risk of infection stratified by current treatment of rheumatoid arthritis

MTX(n = 4206)TNF antagonists(n = 1804)MTX + TNF antagonists(n = 2855)Other DMARDs(n = 1274)
Number of infections17148901514447
Person years of follow-up5141213040311663
Unadjusted rate/100 person-years33.341.837.626.9
Adjusted rate*/100 person-years30.9 (29.2 to 32.7)40.1 (37.0 to 43.4)37.1 (34.9 to 39.3)24.5 (21.8 to 27.5)
  • *Adjusted rates are per 100 person-years estimated with 95% CI in parentheses. Rates were adjusted for age, gender, race, education, duration of rheumatoid arthritis, modified Health Assessment Questionnaire, functional class, physician global, patient global, patient pain, swollen and tender joint counts, body mass index, disability status, liver disorder, lung disease, diabetes, ischaemic heart disease, alcohol use, smoking and prednisone use.

  • DMARD, disease-modifying antirheumatic drug; MTX, methotrexate; TNF, tumour necrosis factor.